Tomorrow Evotec will report her past quarter's results. For this year the consensus of the revenue equals 156,47 million euros. The expectations would mean a record revenue for the company. This is hugely more than the 2015's revenue of 127,68 million euros.
The analysts foresee for 2016 a net profit of 8 million euros. For this year most of the analysts expect a profit per share of 8 cents. Based on the analyst's expectations the price/earnings-ratio is a huge 101,13.
Dividend payments are not expected from Evotec . On average the farmaceut yields a rather high dividend yield of around 1,4 percent.
The stock Evotec is being covered by 5 fundamental analysts. The average target price for the stock is at 7,18 euros. This is around 11 percent less than the current stock price of 8,09 euros. The 3 most recent recommendations for uit Nederland were provided by Berenberg (buy, 9,50 euros), ING (hold, 7,30 euros) and Oddo Seydler Bank (buy, 8,10 euros).
Based on the number of outstanding shares Evotec 's market capitalization equals 1,06 billion euros.At 13.04 the stock traded 0,7 percent lower at 8,09 euros.
ValueSpectrum.com News Wire & Equity Research: +31 084-0032-842
Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.